Loss of the tumor suppressor PTEN led to resistance to the PI3Kα inhibitor BYL-719 (alpelisib) in a breast cancer patient with metastatic breast cancer bearing an activating PIK3CA-mutation (Juric et al., 2015). This evidence concerns the gene PTEN and breast carcinoma.